Crossflow Filter Device for Biotechnological Applications
The Sartocon Slice 50 crossflow filter device can be used for membrane screening and small-volume process development.
The Sartocon Slice 50 crossflow filter device from Sartorius Stedim Biotech (SSB) is designed for use in biotechnological applications, including membrane screening and small-volume process development. The device is offered as an encapsulated crossflow module with a filter area of 50 cm2 and a variety of molecular weight cutoffs. The crossflow filter eliminates the need for a compression holder and comes in a choice of two polymers:
- The Hydrosart membrane is a stable polymer suitable for a broad pH range and can be depyrogenated using sodium hydroxide at elevated temperatures. It is extremely hydrophilic, making it non-protein-binding and virtually non-fouling.
- The polyethersulfone membrane is a stable polymer that is ideal for a broad pH and temperature range.
The Sartocon Slice 50 is linearly scalable and be interfaced with SSB’s recently launched SARTOFLOW Smart benchtop crossflow system, as well as with many other laboratory-scale filtration systems.
Source: Sartorius Stedim Biotech
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
